Supernus Pharmaceuticals
SUPN
218 hedge funds and large institutions have $1.2B invested in Supernus Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 81 increasing their positions, 67 reducing their positions, and 28 closing their positions.
71% more call options, than puts
Call options by funds: $2.04M | Put options by funds: $1.2M
39% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 28
34% more capital invested
Capital invested by funds: $895M → $1.2B (+$305M)
21% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 67
5% more funds holding
Funds holding: 208 → 218 (+10)
2.09% more ownership
Funds ownership: 94.12% → 96.21% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$17.5M |
| 2 |
Renaissance Technologies
New York
|
+$15.3M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$10.6M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$10.1M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$8.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$17.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$15.8M |
| 3 |
Morgan Stanley
New York
|
-$11.5M |
| 4 |
First Manhattan
New York
|
-$10.4M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$9.95M |
SUPN Hedge Fund Activity: Q2 2020 in Review
218 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q2 2020, worth a combined $1.2B — up 34% from $895M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new SUPN positions and 28 closed out — a net gain of 11 holders — while 81 added to existing stakes and 67 trimmed.
The largest buyer was GW&K Investment Management, opening a new position worth an estimated $17.5M. The largest seller was Armistice Capital, cutting an estimated $17.5M.
- 218 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q2 2020, up from 208 in Q1 2020.
- Funds reported $1.2B of Supernus Pharmaceuticals stock for Q2 2020, up 34% quarter-over-quarter.
- 39 funds opened new Supernus Pharmaceuticals positions in Q2 2020 and 28 closed out, a net change of +11 holders.
- The largest Supernus Pharmaceuticals buyer in Q2 2020 was GW&K Investment Management, an estimated $17.5M added.
- The largest Supernus Pharmaceuticals seller in Q2 2020 was Armistice Capital, an estimated $17.5M sold.
Based on aggregated 13F filings for Q2 2020.